2460-33-5

Usage

Uses

Used in Pharmaceutical Research and Development:
(3,4-DIMETHOXYPHENYL)PYRUVIC ACID is utilized as a building block for the synthesis of other organic compounds, facilitating the creation of new drugs and biologically active molecules. Its structure and reactivity provide insights into the behavior of pyruvic acid derivatives, which can be leveraged to design and optimize pharmaceutical agents.
Used in Chemical Research:
In the field of chemical research, (3,4-DIMETHOXYPHENYL)PYRUVIC ACID serves as a model compound for studying the reactivity and behavior of pyruvic acid derivatives. Understanding these properties can inform the development of new synthetic pathways and chemical reactions, expanding the scope of organic chemistry.
Used in Metabolic Studies:
Given its relation to pyruvic acid, a central molecule in glycolysis, (3,4-DIMETHOXYPHENYL)PYRUVIC ACID can be employed in metabolic studies to investigate the role of pyruvic acid and its derivatives in various biological processes. This can lead to a better understanding of metabolic pathways and the potential for targeted therapies in diseases related to metabolism.
Used in Drug Design:
(3,4-DIMETHOXYPHENYL)PYRUVIC ACID is used as a structural component in drug design, where its unique features can be integrated into the development of new pharmaceutical agents. Its presence in a compound may confer specific biological activities or improve the pharmacokinetic properties of a drug candidate, enhancing its therapeutic potential.

Upstream product

• 25349-37-5 (Z)-2-phenyl-4-(3,4-dimethoxybenzylidene)-(4H)-1,3-oxazol-5-one 
• 10040-91-2 5-(3,4-di-methoxybenzylidene)imidazolidine-2,4-dione 
• 461-72-3 2,4-imidazolidinedione 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 41888-65-7 4-(3,4-dimethoxybenzylidene)-2-methyloxazol-5(4H)-one 
• 38879-47-9 (Z)-4-(3,4-dimethoxybenzylidene)-2-methyl-5(4H)-oxazolone 
• 5415-56-5 2-phenyl-4-veratryliden-4H-oxazol-5-one 

Downstream Products

• 6600-61-9 3-(3,4-dimethoxy-benzylidene)-6-methoxy-3H-benzofuran-2-one 
• 84569-66-4 4-[(E)-2-(3,4-Dimethoxy-phenyl)-vinyl]-morpholine 
• 117530-90-2 4-Amino-6-(3,4-dimethoxy-benzyl)-2H-[1,2,4]triazine-3,5-dione 
• 121537-74-4 1-carboxy-2-(3',4'-dimethoxyphenyl)-5-oxocyclohexanol 
• 118739-94-9 4-Amino-6-(3,4-dimethoxy-benzyl)-3-mercapto-4H-[1,2,4]triazin-5-one 
• 117530-87-7 6-(3,4-Dimethoxy-benzyl)-4-phenyl-2H-[1,2,4]triazine-3,5-dione 
• 55-59-4 3-(3,4-dimethoxyphenyl)-2-aminopropionic acid 
• 32161-30-1 (S)-3,4-dimethoxyphenylalanine 
• 96809-04-0 3-benzo[1,3]dioxol-5-yl-2-(3,4-dimethoxy-phenyl)-benzo[f]quinoline-1-carboxylic acid 
• 96465-86-0 5-benzo[1,3]dioxol-5-yl-4-(3,4-dimethoxy-phenyl)-1-(4-nitro-phenyl)-pyrrolidine-2,3-dione 
• 96670-49-4 5-benzo[1,3]dioxol-5-yl-4-(3,4-dimethoxy-phenyl)-1-p-tolyl-pyrrolidine-2,3-dione 
• 22900-94-3 3-(3,4-dimethoxy-phenyl)-2-(4-oxo-2-thioxo-thiazolidin-5-ylidene)-propionic acid 
• 103796-32-3 3-(3,4-dimethoxy-phenyl)-2-hydroxyimino-propionic acid 
• 859951-17-0 N-[(3,4-dimethoxy-phenyl)-acetyl]-3,4-dimethoxy-phenylalanine amide 

Relevant academic research and scientific papers

Chemoenzymatic synthesis of L-3,4-dimethoxyphenyl-alanine and its analogues using aspartate aminotransferase as a key catalyst

In this study, a chemoenzymatic synthesis method for the production of L-3,4-dimethoxyphenyl-alanine and its analogues from phenylpyruvate derivatives was developed. The aspartate aminotransferase from Escherichia coli was engineered by error prone PCR and the improved variants were identified. When 3, 4-dimethoxy phenylpyruvate was added by fed-batch on a preparative scale, L-3,4-dimethoxyphenyl-alanine was formed in 95.4% conversion and > 99% ee with the best aspartate aminotransferase variant as the catalyst. This study provided an efficient method for the production of methoxy substituted phenylalanines using the engineered aspartate aminotransferase.

Bio-inspired enantioselective full transamination using readily available cyclodextrin

The mimics of vitamin B6-dependent enzymes that catalyzed an enantioselective full transamination in the pure aqueous phase have been realized for the first time through the establishment of a new “pyridoxal 5′-phosphate (PLP) catalyzed non-covalent cyclodextrin (CD)-keto acid inclusion complexes” system, and various optically active amino acids have been obtained.

Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets

Psammaplin A (11c) is a marine metabolite previously reported to be a potent inhibitor of two classes of epigenetic enzymes: histone deacetylases and DNA methyltransferases. The design and synthesis of a focused library based on the psammaplin A core has been carried out to probe the molecular features of this molecule responsible for its activity. By direct in vitro assay of the free thiol generated upon reduction of the dimeric psammaplin scaffold, we have unambiguously demonstrated that 11c functions as a natural prodrug, with the reduced form being highly potent against HDAC1 in vitro (IC50 0.9 nM). Furthermore, we have shown it to have high isoform selectivity, being 360-fold selective for HDAC1 over HDAC6 and more than 1000-fold less potent against HDAC7 and HDAC8. SAR around our focused library revealed a number of features, most notably the oxime functionality to be important to this selectivity. Many of the compounds show significant cytotoxicity in A549, MCF7, and W138 cells, with the SAR of cytotoxicity correlating to HDAC inhibition. Furthermore, compound treatment causes upregulation of histone acetylation but little effect on tubulin acetylation. Finally, we have found no evidence for 11c functioning as a DNMT inhibitor.

Method for preparing chiral diphosphines

The invention concerns a method for preparing a compound of formula (1) wherein: A represents naphthyl or phenyl optionally substituted; and Ar1, Ar2independently represent a saturated or aromatic carbocyclic group, optionally substituted.

Asymmetric hydrogenation method of a ketonic compound and derivative

The present invention relates to a process for the asymmetric hydrogenation of a ketonic compound and derivative. The invention relates to the use of optically active metal complexes as catalysts for the asymmetric hydrogenation of a ketonic compound and derivative. The process for the asymmetric hydrogenation of a ketonic compound and derivative is characterized in that the asymmetric hydrogenation of said compound is carried out in the presence of an effective amount of a metal complex comprising as ligand an optically active diphosphine corresponding to one of the following formulae: STR1

Potent, selective tetrahydro-β-carboline antagonists of the serotonin 2B (5HT(2B)) contractile receptor in the rat stomach fundus

A series of potent, selective 5HT(2B) receptor antagonists has been identified based upon yohimbine, with SAR studies resulting in a 1000-fold increase in 5HT(2B) receptor affinity relative to the starting structure (- log K(B)s > 10.0 have been obtained). These high-affinity tetrahydro-β- carboline antagonists are able to discriminate among the 5HT2 family of serotonin receptors, with members of the series showing selectivities of more than 100-fold versus both the 5HT(2A) and 5HT(2C) receptors based upon radioligand binding and functional assays. As the first compounds reported with such selectivity and enhanced receptor affinity, these tetrahydro-β- carboline antagonists are useful tools for elucidating the role of serotonin acting at the 5HT(2B) receptor in normal and disease physiology.

An expedient synthesis of isopropyl anisoles and veratroles

Isopropyl-substituted anisoles and veratroles were obtained in high yields (89-93%) on the aqueous work-up of the reaction of 3-(methoxyphenyl)-2-oxopropanoic acids with iodomethane and potassium hydroxide in dimethyl sulfoxide.